See how Eli Lilly and Company and Walmart Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$1,179.11
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
Founded in 1962, Walmart Inc. has grown into the world’s largest retailer, operating more than 10,700 stores worldwide, including about 4,600 Walmart locations in the United States and roughly 600 Sam’s Club warehouses, while continuing to expand its e-commerce business. The company serves around 270 million customers each week and generated over $680 billion in fiscal 2025 revenue. Walmart’s operations are organized into three reporting segments: Walmart U.S., which accounted for 68% of fiscal 2025 sales, Walmart International at 18%, and Sam’s Club at 14%. In the U.S., nearly 60% of Walmart’s $465 billion in fiscal 2025 revenue came from grocery sales, with about one-quarter generated by general merchandise. Internationally, the company’s business is primarily concentrated in Mexico, with additional emerging exposure to India.